Gene-Editing Companies To Watch At J.P. Morgan
Milestones Expected In 2022 For CRISPR and Emerging Technologies
Editas's first in vivo gene therapy results underwhelmed last year, but the company could build on its leading position in 2022. • Source: Alamy 
